BAD HOMBURG, GERMANY, Dec 5, 2024 - (ACN Newswire via SeaPRwire.com) - Maxon, maker of powerful, approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects, and more, today released updates across its Maxon One product suite, with new features in Cinema 4D, Redshift, ZBrush and ZBrush for iPad, and Red Giant. The release fulfills artists' holiday wishlists with new capabilities that enhance everyday workflows and improve quality of life for artists, animators, VFX professionals, and studios.Image courtesy of Patrick 4DWhether it's crafting unique models using brand new Cinema 4D Booleans that give cookie-cutter a whole new meaning or bringing a dazzling snowfall to life with Cinema 4D Particles, Maxon One makes it all possible. GoZ in ZBrush for iPad now makes it even easier to transfer creations from the comfort of your couch to the power of your PC or Mac, where the magic of ZBrush, Cinema 4D, Red Giant and Redshift bring those visions to life."From broadcast and film to branding, character creation to world-building, there is no corner of art and design that Maxon One tools do not touch, and with every new release, we aim to make the lives of creative professionals that much easier and more enjoyable - and what better time to bring the joy than the holidays?" said Philip Losch, CPTO of Maxon. "This update delivers improvements based on community input, from the powerful new Boolean workflows in Cinema 4D to cross platform workflows with ZBrush for iPad. Each enhancement inspires innovation across diverse creative fields that permeate through our everyday lives, whether that's on the screen, in the creation of consumer goods or architectural design, and even medical animation of world-changing ideas."Baking Holiday Magic With Patrick 4D3D artist and "Digital Chef" Patrick 4D, who specializes in digital photorealism for food and products, is teaming up with Maxon to bake up some digital goodies for the holiday season: a collection of gingerbread cookies crafted in ZBrush. Available now in the trial or full version of ZBrush, artists can make the cookies their own with tasty decorations and world building. To join in on the fun, share your creations with the Maxon community by tagging @maxonvfx on Instagram.Models That are Anything but Cookie-Cutter with Cinema 4DCinema 4D 2025.1 introduces a completely new Boolean generator that allows artists to easily create complex shapes from animated elements, streamlining the modeling process through intuitive shape addition and subtraction. This new algorithm is faster and more robust, enabling users to work with complex geometry while maintaining high frame rates, even with intricate animated booleans. The flexible user interface allows for the combination of multiple inputs and operations into a single boolean object, a significant upgrade from the previous limitation of just two inputs.In Cinema 4D, precise control over particle behavior is now possible with custom properties and the Particle Node Modifier, part of the growing GPU-accelerated Unified Simulation toolset, offering greater flexibility and creativity. Existing customers will appreciate quality-of-life improvements in Cinema 4D, including enhanced USD import/export and improvements to XRef performance and reliability for seamless collaboration. Interactive tutorials in the Learning Panel combine video guidance and UI highlights to simplify concepts and accelerate the learning process.Redshift Renders Really Fly With an AI Boost and Improved VisualizationRedshift combined with Cinema 4D and ZBrush are the ultimate building blocks for character and product design and architectural visualization, empowering creative professionals to craft breathtaking designs and models that transport clients to new dimensions. Redshift 2025.2 brings continued improvements to Toon rendering, even faster renders in ZBrush and Cinema 4D, and support for fully three-dimensional contours.Tightening of the Substance integrations gives users a fantastic workflow across Adobe and Maxon solutions (available as a bundle). Redshift Random Material Switch makes it easy to vary materials across MoGraph clones and other objects, while improved cross-platform AI-based denoising enables faster and more efficient renders.Creativity Unwrapped with ZBrush (for iPad)The cross-platform compatibility for ZBrush creations continues to see enhancements, with the ability to transfer with just a few clicks from iPad to desktop, where artists can refine, add animation and materials, and render. The complete workflow from concept to render starts the moment creativity strikes thanks to GoZ technology, and for the first time, artists can exchange creations bidirectionally between ZBrush for iPad and Cinema 4D. GoZ has also simplified the process of sending ZBrush sculpts to the 2025 versions of Maya and 3DSMAX.ZBrush desktop also now includes faster Redshift rendering, with denoising and separate AOV passes for shadows, reflections and more to more easily composite in Photoshop. The Anchor Brush in ZBrush for Desktop now has a new Bend mode, allowing users to easily pose characters using two anchor points.Additional updates to ZBrush for iPad, released in November, include UV and texture mapping, surface noise, localization, and improved support for Apple Pencil Pro. ZBrush for iPad includes nearly all the power of the full desktop application, and Maxon continues to close the gap with popular features to customize surfacing.Feeling Festive and On-Trend with Red Giant and Maxon StudioMaxon One's powerhouse for adding personal or branded flair to any project, Red Giant 2025.2 includes updates in Maxon Studio and Universe that make it easy for content creators to level up their videos with on-trend effects, transitions and motion templates. 2D Motion Designers and Compositors can get started easily with the help of Maxon Studio, an After Effects templating toolkit that offers hundreds of customizable graphics and effects, including a set of meticulously crafted Film Title templates. And, always on trend, Universe and Red Giant subscribers can now make use of six new Pixel Dither effects for effortless pixel art creation, using advanced dithering effects that capture the essence of retro gaming and animation.About MaxonMaxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon's innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.Press ContactMegan FasyGrithaus Agency(e) megan@grithaus.agency(p) +1 (617) 480-3674SOURCE: Maxon Computers Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - How much sugar does a Singaporean typically take in a day? In a recent speech by Health Minister Mr. Ong Ye Kung, Singapore is too sweet. While the average daily sugar intake of Singaporeans has fallen from 60g in 2018 to 56g in 2022, this number still works out to about 11 teaspoons of daily sugar consumption, about 10% higher than the ideal intake of less than 50g.Amid an ageing population, the younger generation in Singapore is also increasingly affected by this chronic condition, highlighting a growing national health concern related to sugar consumption.Sugar, a common mis-solution to anxiety, often provides a sense of fleeting comfort. The instant boost in dopamine from sugar can create a cycle of dependency, giving temporary relief from stress or anxiety but contributing to harmful physical effects, such as inflammation, weight gain, and insulin resistance.The overconsumption of sugar, combined with sedentary lifestyles and other unhealthy dietary habits have contributed to diabetes becoming a major global health crisis today – Alarmingly, diabetes rates are rising among the younger generation, including both teenagers and young adults, contributing to nearly half a million cases in Singapore. Astonishingly, 40% of Singaporeans remain unaware of their pre-diabetic status, an often silent condition that could lead to type 2 diabetes.Diabetes is a chronic condition that if left unmanaged, can lead to serious health complications, including an increased risk of cardiovascular disease, kidney failure, nerve damage or even vision loss. However, type 2 diabetes can be prevented through proactive lifestyle changes, including healthy eating, regular physical activity, so as to maintain optimal blood sugar levels.In line with World Diabetes Day on 14 November, LAC (pronounced as L-A-C) is dedicated to highlight the importance of taking preventative measures against diabetes. By incorporating supplements that support blood sugar regulation and reduce carbohydrate absorption, along with a healthy diet and increased physical activity, individuals can maintain their glucose levels and maintain their metabolic health.LAC GlucoX is designed to support healthy glucose levels. Formulated with bitter melon and Fibersol-2, Banaba leaf, Gymnema, Chromium and Brown Seaweed, GlucoX helps slow down carbohydrate absorption and optimises glucose utilisation, supporting individuals in managing their blood sugar levels effectively.LAC Bitter Melon Formula, is formulated with Momordica Charantia Polysaccharide (MCP), a key compound from bitter melon known for its ability to support healthy blood glucose levels. It enhances the body’s ability to regulate insulin production and supports the overall metabolic health of individuals. Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN FRANCISCO, CA & MUMBAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - CleverTap, the all-in-one engagement platform, has released its market research report on “The State of App and Web User Experience Optimization”. The report sheds light on how digital-first brands are leveraging experimentation and personalization on their apps and websites to drive customer engagement and business growth. It also highlights roadblocks faced by marketers and product managers while experimenting with the UI, workflows, and functionality across apps and websites.For a thorough understanding of the current landscape, this report draws insights from a diverse group of respondents – with data gathered through structured surveys and in-depth interviews – representing organizations with over two million customers across 50+ countries. This includes VPs, CMOs, and product managers ranging from startups to large enterprises across various industries. – Together, they offer valuable insights into how businesses optimize app and web experiences to drive customer engagement and business growth.While 95% of surveyed product managers and 88% of marketers believe that the right user experience is essential for driving customer engagement and retention — many report significant challenges to effectively experimenting with app and web user experiences. Despite recognizing its importance, they reported difficulties such as limited resources, data gaps, and technical constraints that hinder their ability to innovate and deliver impactful user experiences. Other notable findings from the report include -81.9% of product managers rarely experiment with their app and web experiences before making changes to them. The top challenges quoted include lack of resources (46%), inadequate data and analytics (31%), and technical issues (19%)54% of product managers are unable to support marketers in experimenting with onboarding flows, banner placement, homepage content and other similar app and web experiences.81% of marketers believe it would make a significant impact if they could independently experiment with multiple variations of web and app experiences within a no-code framework provided by their product management function.Commenting on the report, Jacob Joseph, Vice President - Data Science, CleverTap said, “With consumer expectations constantly rising, brands need to go beyond perfecting their channel strategies and also focus on enhancing the in-app and web experiences to drive results from their marketing efforts. Since all channels ultimately lead users to the app or website, an unsatisfactory experience there can render all your efforts ineffective and become a missed opportunity. Personalization and experimentation on apps and websites are critical to reducing churn and driving growth, yet resource constraints and data gaps hinder marketers and product managers. We are committed to helping businesses navigate these challenges with CleverTap’s Product Experiences, which offers effortless ways to personalize and experiment with app and web experiences driving stronger engagement and lasting brand loyalty."For more information and insights download the report here. About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.comASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.

- Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.- In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24.- EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported.SHANGHAI, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK,“Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. In an analysis of the data available as of September 13th, 2024, results from the Phase 1b/2a clinical trial showed that for patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission1 and 10 out of 11 (91%) achieved immunological complete remission (ICR)2. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved ICR by week 24.EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintaining high potency, thereby potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors. Everest Medicines holds global rights to EVER001 for the treatment of renal diseases.The Phase 1b/2a clinical trial of EVER001 for the treatment of pMN is an ongoing trial conducted in China. A total of 31 patients with biopsy-proven pMN who tested positive for anti-PLA2R autoantibodies were enrolled into two cohorts. The total treatment duration was 36 weeks. Based on the patient data collected by September 13th, 2024, in the low-dose cohort, the geometric least squares mean 24-hour proteinuria decreased by 78.3% at week 36 compared to baseline, while the high-dose cohort achieved a 73.8% reduction by week 24. EVER001 treatment induced greater than 90% reductions in anti-PLA2R antibody as early as week 24 in the low-dose cohort and week 12 in the high-dose cohort. EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported."We are excited to see the encouraging results in this preliminary analysis of our Phase 1b/2a clinical proof-of-concept trial of EVER001. This demonstrates the potential of EVER001 as a next-generation BTK inhibitor for the treatment of various autoimmune renal diseases, including pMN. "Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said："This data release marks the first time Everest Medicines has disclosed results from its global pipeline. We look forward to completing this trial and sharing detailed data in future conferences and publications. Moving forward, we will continue to drive the global clinical development of EVER001, to meet patients' urgent clinical needs.”Membranous nephropathy is a common pathological type of nephrotic syndrome in adults, and its prevalence in China has been increasing, ranking second only to IgA nephropathy3. There are about 2 million patients with pMN in China, with an estimated 80,000 to 100,000 patients in the United States, 80,000 in Europe, and 40,000 in Japan. There are no approved drugs for this indication worldwide. The current treatment goal is to improve remission rates, reduce high relapse rates, and minimize the risk of chronic toxicity caused by currently available treatments. More than one-third of pMN patients still progress to end-stage renal disease under current standards of care.This Phase 1b/2a clinical trial was approved by the Center for Drug Evaluation of the National Medical Products Administration in September 2022 to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. The previously published results of a Phase 1 study conducted in healthy Chinese and Australian subjects conducted by SinoMab BioScience indicate that EVER001 has high selectivity, excellent pharmacokinetic properties, a good safety profile, and strong target binding.About EVER001EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 trial with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, strong target binding and a safety profile that supports continued clinical development.Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases.Investor Calls InformationEverest Medicines will hold investor calls on the data results from EVER001 Phase 1b/2a clinical study in primary membranous nephropathy. EVER001 is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, and Everest owns the global rights to develop EVER001 for the treatment of renal diseases.The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024, Beijing Time (8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on Dec. 3, 2024).The conference calls can be accessed by the following links:For English Session:Time: 9:00 AM Beijing Time, Wednesday, Dec. 4, 2024 (8:00 PM U.S. Eastern Time on Dec. 3, 2024)Pre-Registration Link: https://www.acecamptech.com/eventDetail/60510700Webcast Link:https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700Alternatively, participants may dial in to the conference call using below dial-in information:United States: +1-646-2543594 (EN)Chinese Mainland: +86-10-58084166 (EN), +86-10-58084199 (CN)Hong Kong, China: +852-30051313 (EN), +852-30051355 (CN)United Kingdom: +44-12-1368-0466 (EN)International: +1-866-6363243 (EN)Password: 842080For Mandarin Session:Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024)Webcast Link: https://s.comein.cn/n3arj55sAlternatively, participants may dial into the conference call using below dial-in information:United States: +1-646-3578788, +1-408-7093255Chinese Mainland: 400-969-8928, 400-806-3263Hong Kong, China: +852-301-83602Taiwan, China: +886-226563394, +886-277417882Singapore: +65-64075649, +65-66220840United Kingdom: +44-2070970018 International: +86-2362737123Password: 377570The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.References:1.Overall clinical remission (complete remission or partial remission): 24h proteinuria complete remission (CR): 24h proteinuria < 0.3g/24 h; 24h proteinuria partial remission (PR): 24h proteinuria < 3.5g/24h, but ≥0.3g/24 h, and reduction > 50%, regardless of eGFR or the serum albumin level from baseline.2. Immunological complete remission (ICR): anti-PLA2R titer < 20RU/ml (negative).3. Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3. Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - OKX, the leading cryptocurrency exchange, has partnered with DeAgentAI, the first AI-driven feedback incentive protocol in Web3, to launch an exclusive airdrop campaign. Starting December 3rd, users can complete simple tasks on OKX Wallet to win a share of $50,000 worth of DA tokens.Click here to join the campaign: https://www.okx.com/web3/giveawayParticipating in the DeAgentAI and OKX Wallet airdrop is easy. Download the OKX Wallet, follow DeAgentAI social media networks, and complete a few simple tasks such as sharing campaign posts, and you can claim your rewards. The campaign runs from December 3rd for two weeks-don't miss out!This collaboration brings users unparalleled opportunities to explore advanced AI technology while enjoying the benefits of a secure and user-friendly wallet. With rewards of $50,000 worth of DA tokens, the initiative encourages users to explore Web3 in an innovative and incentivized environment. DeAgentAI and OKX Wallet aim to foster adoption and empower users in the rapidly evolving crypto space.About DeAgentAIDeAgentAI is a trailblazer in Web3 technology, introducing the first AI feedback mechanism incentive protocol that achieves "proof of insight" by integrating user feedback into the model training process. Its flagship product, AlphaX, combines advanced MOE and Transformer architectures to predict BTC and ETH price trends with over 80% accuracy.What is OKX's Web3 Wallet?OKX Wallet complements this innovation with its secure and user-friendly interface tailored for decentralized finance (DeFi) and Web3 applications. As a leading wallet in the crypto space, OKX Wallet enables seamless integration with platforms like DeAgentAI, empowering users to engage in token giveaways, explore cutting-edge AI tools, and participate in the rapidly growing Web3 ecosystem.Contact InformationYves-Alexandre d'OuradouFounderdeagent.ai@gmail.com(001) 2024989991Source: DeAgentAI Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Maritime Self-Defense Force (JMSDF) has selected the General Atomics Aeronautical Systems, Inc. (GA-ASI) SeaGuardian® Remotely Piloted Aircraft (RPA) systems for its Long Endurance Unmanned Aerial Vehicle program. This follows JMSDF use of SeaGuardian since May 2023 as part of its Medium-Altitude, Long Endurance (MALE) RPA System Trial Operations Project.SeaGuardian has been used by JMSDF to conduct various tests including whether unmanned aircraft can supplant some of the missions currently accomplished with manned aircraft. SeaGuardian is a MALE RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.SeaGuardian features two multi-mode maritime surface-search radars with an Inverse Synthetic Aperture Radar (ISAR) imaging mode, an Automatic Identification System (AIS) receiver, and a High-Definition - Full-Motion Video sensor equipped with optical and infrared cameras as well as electronic intelligence receivers. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles and provides automatic tracking of maritime targets and correlation of AIS transmitters with radar and electronic intelligence tracks.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com .Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 3, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") a leading North American exploration company focused on critical minerals, acknowledges today's announcement by China banning exports of gallium, germanium, and antimony to the United States. This move underscores the urgent need for Western nations to secure reliable long-term sources of these essential materials.Antimony, a critical component in military applications, energy storage, and advanced manufacturing, is now at the forefront of the global supply chain crisis. China's ban, coupled with existing restrictions that came into effect September 15, 2024, has already sent antimony prices soaring by over 228% this year(1). The Western world faces mounting pressure to address its reliance on China for strategic resources critical to national defense and technological innovation. This ban comes at a time when defense sector inventories are at already concerningly low levels.(2)Military Metals recent antimony mineral project acquisitions in Slovakia, Nova Scotia, and Nevada provide shareholders with a pure antimony play with a diverse portfolio in top jurisdictions."This announcement from China reinforces the importance of Military Metals' mission to secure a sustainable, independent future supply chain for critical minerals," said Scott Eldridge, CEO of Military Metals Corp. "The West can no longer afford to rely on adversarial nations for resources essential to our security and economic stability. We are taking proactive steps to meet this growing demand with future domestic and allied sources of antimony."As geopolitical tensions escalate and the trade war intensifies, Military Metals will continue to prioritize the development of critical mineral resources and work closely with governments and industry partners to ensure the West remains resilient and self-sufficient.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release include exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties.. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.(1)Reuters; China bans export of critical minerals to US as trade tensions escalate; By Amy Lv and Tony Munroe; December 3, 2024(2)Heritage Foundation: commentary/It’s Past Time to Re-Supply Our Munitions-Depleted U.S. Navy by Jim Fein; June 17, 2024To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232325 Copyright 2024 ACN Newswire via SeaPRwire.com.

TSUKUBA, Japan, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Polymers, such as plastics, are essential in many aspects of life and industry, from packaging and cars to medical devices and optic fibres. Their value comes from diverse properties that are largely determined by their monomers – the single chemical units – that make up a polymer. Unfortunately, it can be challenging to control the chemical behaviour of monomers during manufacture to achieve a desired outcome.The flow synthesis reactor with two bottles containing a monomer, initiator and solvent mixed using a micromixer. The synthesis is controlled with AI-based design of experimental conditions such as the temperature and a flow rate. Now, a team of researchers led by Professor Mikiya Fujii of the Nara Institute of Science and Technology in Japan have used machine learning to mathematically model the polymerization process and reduce the need for time-consuming and expensive experimentation. Their results have been published in the journal Science and Technology of Advanced Materials: Methods.Machine learning algorithms need data, so the researchers designed a polymerization process that would quickly and efficiently generate experimental data to feed into the mathematical model. The target molecule was a styrene-methyl methacrylate co-polymer, which was made by mixing styrene and methyl methacrylate monomers, both already dissolved in a solvent with an added initiator substance, then heating them in a water bath.The team also used a method called flow synthesis, in which the two monomer solutions are mixed and heated in a constant flow. This allows for better mixing, more efficient heating, and more precise control of heating time and flow rate, which makes it ideal for use with machine learning.The modelling evaluated the effect of five key variables in the polymerization process: the concentration of the initiator, the ratio of solvent to monomer, the proportion of styrene, the temperature of the reaction, and the time spent in the water bath. The goal was to have an end product with as close to 50% styrene as possible.Once enough experimental data was available, the machine learning process took only five cycles of calculation to achieve the ideal proportion of styrene to methyl methacrylate. The results showed that the key was a lower temperature and longer time in the water bath, as well as lowering the relative concentration of the monomer in the solvent. The researchers were surprised to discover that the solvent concentration was just as important as the proportion of monomers going into the mix.“Our results demonstrate that machine learning not only can explicitly reveal what humans may have implicitly taken for granted but can also provide new insights that weren’t recognized before,” Professor Mikiya Fujii says. “The use of machine learning in chemistry could open the door for smarter, greener manufacturing processes with reduced waste and energy consumption.”Further informationMikiya FujiiNara Institute of Science and TechnologyEmail: fujii.mikiya@ms.naist.jp Paper: https://doi.org/10.1080/27660400.2024.2425178About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-M Dr Yasufumi NakamichiSTAM Publishing DirectorEmail: NAKAMICHI.Yasufumi@nims.go.jp Press release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2024 ACN Newswire via SeaPRwire.com.

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.